The impact of a regionally based translational cancer research collaborative in Australia using the FAIT methodology
Christine Paul(Hunter Medical Research Institute), Shanthi Ramanathan(Hunter Medical Research Institute), Rodney J. Scott(New South Wales Department of Health), Susan Goode(Hunter Medical Research Institute), Jarad Martin(Calvary Mater Newcastle Hospital), Nick Zdenkowski(University of Newcastle Australia), Sarah M. Nielsen(Myriad (Germany)), James Lynam, Peter B. Greer(Calvary Mater Newcastle Hospital), Andrew Searles(Hunter Medical Research Institute), Stephen P. Ackland(Mater Misericordiae Hospital), Anne Thomas(Leicester Royal Infirmary), Nicole M. Verrills(Hunter Medical Research Institute), Kelly A. Avery‐Kiejda(John Hunter Hospital), Elizabeth A. Fradgley(Hunter Medical Research Institute), Judith Weidenhofer(Hunter Medical Research Institute), Sarah Lukeman(University of Newcastle Australia), Cassandra P. Griffin(Hunter Medical Research Institute)
Cited by 1
Related Papers
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k
Reaching the hard-to-reach: a systematic review of strategies for improving health and medical research with socially disadvantaged groups
|BMC Medical Research Methodology|2014|1.5k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Inflammatory subtypes in asthma: Assessment and identification using induced sputum
|Respirology|2006|939